Related topics: patients , health care , children , heart attack , women
The New England Journal of Medicine
hideThe New England Journal of Medicine (N Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. It is also the oldest continuously published medical journal in the world.
For more information about The New England Journal of Medicine, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
News tagged with new england journal of medicine
Study reveals lack of diversity in embryonic stem cell lines
Dec 16, 2009 |
5 / 5 (1) |
0
The most widely used human embryonic stem cell lines lack genetic diversity, a finding that raises social justice questions that must be addressed to ensure that all sectors of society benefit from stem cell advances, according ...
Researchers publish review of the 'molecular basis of colorectal cancer'
Dec 16, 2009 |
4 / 5 (1) |
0
Every year in the United States, 160,000 cases of colorectal cancer are diagnosed, and 57,000 patients die of the disease, making it the second leading cause of death from cancer among adults, after lung cancer.
Leprosy susceptibility genes reported
Dec 16, 2009 |
not rated yet |
0
In the first genome-wide association study (GWAS) of leprosy and the largest GWAS on an infectious disease, scientists at the Genome Institute of Singapore (GIS) and 26 institutes in China identified seven genes that increase ...
Genetic variant may control lung function and risk of COPD
Dec 17, 2009 |
not rated yet |
0
Researchers have discovered evidence that suggests a genetic variant may be associated with better preserved lung function among children with asthma and adults who smoke, according to a new study funded by the National Heart, ...
Anemia drug not helpful for kidney disease patients
9 hours ago |
not rated yet |
1
An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.
